The following questions and topics will be covered in this presentation.
Buprenorphine: Opioid Agonist-Antagonist Benefits for Opioid Resistant Pain, Uncontrolled By Full-Agonist Opioids During Hematopoietic Stem Cell Transplant for Sickle Cell Disease: Dr. Mayuko Sakae
1. Which of the following buprenorphine pharmacodynamics is correct?
a. Partial kappa opioid receptor agonism
b. Mu opioid receptor antagonist
c. Delta opioid receptor agonism
d. Partial mu-opioid receptor agonism
e. Opioid Receptor Like-1 antagonism
2. Which of the following conditions is a contraindication for buprenorphine use?
a. Renal insufficiency
b. Cancer
c. Sickle cell disease
d. Chronic obstructive pulmonary disease
e. None of the above
3. Which opioid side effect is less likely to occur by buprenorphine compared to other traditional opioids?
a. Pruritis
b. Delirium
c. Constipation
d. Urinary retention
e. Myoclonus
4. Which of the following opioid analgesic regimen will be the safest in liver impairment?
a. Scheduled morphine extended-release and acetaminophen as needed for breakthrough pain
b. Scheduled buprenorphine and hydrocodone as needed for breakthrough pain
c. Schedule hydrocodone extended-release and buprenorphine as needed for breakthrough pain
d. Scheduled buprenorphine and hydromorphone as needed for breakthrough pain
e. Scheduled oxycodone extended-release and morphine as needed for breakthrough pain
5. Which of the following complication(s) is less associated with buprenorphine compared to morphine/oxycodone?
a. Addiction
b. Anxiety
c. Respiratory depression
d. Hypogonadism
e. All the above
